Sleep

The world today seems like a busy place - pressure on us to hurry, get things done, burn the midnight oil, cram, sleep when absolutely necessary. I'm here to tell you that with lymphoma (and afterwards for some) that will change.



Treatments will leave you tired. Your body will need rest to fight the cancer. I'm not saying you'll stay in bed all through treatment - I worked 9 days out of 10 most 2 week periods (1 day for chemo, 1 weekend nauseated). But your friend is the nap. Naps are good. If just for 15-45 minutes, you'll be better off.



And make sure you get a full nights rest too.



Also plan your sleeping areas. Yes, areas, you can have more than one. our bedroom is important - get comfy, maybe put a TV or books or other distractions in there if you are awake but still in bed. You can also make alternate areas - a couch with a pillow & blanket or an armchair. In my case, we set up a bed in the family room as we had extra bedding and I was always welcome to crawl in there & rest and still be with family members.



Plan and rest. Part of getting through this time.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap